Rachel McMinn - 22 Sep 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: NGNE
Reported as of: 22 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 14:49:12 UTC
Prior SEC filing: 30 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Donna M. Cochener, as attorney-in-fact for Rachel McMinn

Key filing fact

Rachel McMinn filed Form 4 for Neurogene Inc. (NGNE) on 02 Oct 2026.

Key facts

This page summarizes Rachel McMinn's Form 4 filing for Neurogene Inc. (NGNE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2026, 14:49.

Change

Previous filing in this sequence was filed on 30 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001606302 Primary reporting owner

McMinn Rachel

Relationship: Chief Executive Officer, Director
Address: C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK
Signature: /s/ Donna M. Cochener, as attorney-in-fact for Rachel McMinn
Signature date: 02 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NGNE transaction

Common Stock

Options Exercise

Transaction value
Shares: +756
Change %: +0.06%
Price: $25.32^*
Shares after: 1,345,063
Date: 22 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NGNE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -756
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 22 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 756
Exercise price: $25.32
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.

Footnote F2

This option is fully vested and exercisable.